View in EDS HTML Full Text PDF Full Text

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy.

Saved in:
Bibliographic Details
Title: Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy.
Authors: Zhang M; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Yuan H; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China., Pan X; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Li X; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Wang Z; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China., Zhang S; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Gu Z; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Hu B; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Qu X; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Wang Q; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Gu X; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Wang B; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Cao Y; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Mu G; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Kang G; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China., de Marco A; Laboratory for Environmental and Life Sciences, University of Nova Gorica, Nova Gorica, Slovenia., Zhou X; China Resources Biopharmaceutical Company Limited, Shenzhen, China., Huang H; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
Source: Frontiers in immunology [Front Immunol] 2026 Jun 10; Vol. 17, pp. 1861537. Date of Electronic Publication: 2026 Jun 10 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42358951
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+M%22">Zhang M</searchLink>; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Yuan+H%22">Yuan H</searchLink>; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Pan+X%22">Pan X</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Wang+Z%22">Wang Z</searchLink>; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Zhang+S%22">Zhang S</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Gu+Z%22">Gu Z</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Hu+B%22">Hu B</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Qu+X%22">Qu X</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Wang+Q%22">Wang Q</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Gu+X%22">Gu X</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Wang+B%22">Wang B</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Cao+Y%22">Cao Y</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Mu+G%22">Mu G</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Kang+G%22">Kang G</searchLink>; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22de+Marco+A%22">de Marco A</searchLink>; Laboratory for Environmental and Life Sciences, University of Nova Gorica, Nova Gorica, Slovenia.<br /><searchLink fieldCode="AU" term="%22Zhou+X%22">Zhou X</searchLink>; China Resources Biopharmaceutical Company Limited, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Huang+H%22">Huang H</searchLink>; School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Tianjin Key Laboratory of Biological and Pharmaceutical Engineering, Tianjin University, Tianjin, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 Jun 10; Vol. 17, pp. 1861537. <i>Date of Electronic Publication: </i>2026 Jun 10 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42358951
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2026.1861537
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1861537
    Titles:
      – TitleFull: Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang M
      – PersonEntity:
          Name:
            NameFull: Yuan H
      – PersonEntity:
          Name:
            NameFull: Pan X
      – PersonEntity:
          Name:
            NameFull: Li X
      – PersonEntity:
          Name:
            NameFull: Wang Z
      – PersonEntity:
          Name:
            NameFull: Zhang S
      – PersonEntity:
          Name:
            NameFull: Gu Z
      – PersonEntity:
          Name:
            NameFull: Hu B
      – PersonEntity:
          Name:
            NameFull: Qu X
      – PersonEntity:
          Name:
            NameFull: Wang Q
      – PersonEntity:
          Name:
            NameFull: Gu X
      – PersonEntity:
          Name:
            NameFull: Wang B
      – PersonEntity:
          Name:
            NameFull: Cao Y
      – PersonEntity:
          Name:
            NameFull: Mu G
      – PersonEntity:
          Name:
            NameFull: Kang G
      – PersonEntity:
          Name:
            NameFull: de Marco A
      – PersonEntity:
          Name:
            NameFull: Zhou X
      – PersonEntity:
          Name:
            NameFull: Huang H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 06
              Text: 2026 Jun 10
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1